Cross-sectional Study

National early warning score (NEWS) 2 predicts hospital mortality from COVID-19 patients

Eric Wibisono, Usman Hadi, Bramantono, Muhammad Vitanata Arfijanto, Muso Rusli, Brian Eka Rahman, Tri Pudy Asmarawati, Miftahani Leo Choirunnisa, Dwi Retno Puji Rahayu

A Department of Internal Medicine, Faculty of Medicine, Universitas Airlangga – Dr. Soetomo General Academic Hospital, Surabaya, Indonesia
B Department of Internal Medicine, Faculty of Medicine, Universitas Airlangga – Airlangga University Teaching Hospital, Surabaya, Indonesia

ARTICLE INFO

Keywords:
Comorbid disease
COVID-19
Mortality
National early warning score

ABSTRACT

Background: COVID-19 has a high risk of mortality, especially in patients with comorbid diseases such as cardiac disease, type 2 diabetes mellitus, chronic kidney disease, and hypertension. The National Early Warning Score (NEWS) is a tool that helps in identifying changes in patient conditions that require intensive treatment.

Objective: Analyzing NEWS-2 to identify the risk of death in COVID-19 patients.

Methods: This research was conducted from June to July 2020 by using quota sampling. The number of participants in this study was 112 participants (case group = 56 participants and control group = 56 participants). Participants were assessed for NEWS-2 and evaluated for their treatment outcomes. The analysis used in this study was the Chi-squared test and logistic regression with p < 0.05.

Results: 45 participants died of having NEWS-2 score >5, and as many as 50 participants showed an improvement in their condition by having NEWS-2 score ≤5. The accuracy of NEWS-2’s assessment of mortality of COVID-19 patients had a sensitivity of 80.4% and a specificity of 89.3%. There were several comorbid diseases that had a significant relationship on mortality of COVID-19 patients such as cardiac disease (β = 5.907; 1.107–31.527 95% CI; p = 0.038), T2DM (β = 3.143; 1.269–7.783 95% CI; p = 0.013), CKD (β = 3.851; 1.195–12.416 95% CI; p = 0.024), and hypertension (β = 2.820; 1.075–7.399 95% CI; p = 0.035).

Conclusion: The NEWS-2 can be used to identify the risk of death of COVID-19 patients.

1. Introduction

The COVID-19 is an infectious disease caused by the SAR-COV-2 virus, which is a single-stranded RNA virus that was first discovered in Wuhan, China in December 2019. On March 11, 2020, WHO announced that COVID-19 had become a worldwide pandemic. On May 25, 2021, the number of confirmed COVID-19 cases in the world reached 168,599,045 cases, with the death toll reaching 3,507,477 cases. In Indonesia, the number of confirmed COVID-19 cases was 1,797,499 cases, the death rate was 49,907 cases and the recovered cases were 1,642,074 cases, while for the province of East Java there were 153,596 confirmed cases, while for the province of East Java there were 153,596 confirmed cases.

During the COVID-19 pandemic, tools are needed to quickly and accurately evaluate the condition of COVID-19 patients, so we are interested in using the national early warning score-2 (NEWS 2) on COVID-19 patients [5]. The National Early Warning Score (NEWS) is an assessment based on physiology quickly involving vital signs which were originally developed to track and identify the risk of worsening of patients hospitalized in non-intensive care rooms with the aim of initial stabilization and referral to intensive care rooms. The NEWS is often used as an accurate predictor of mortality and ICU admission in non-COVID-19 patients [5]. During the COVID-19 pandemic, tools are needed to quickly and accurately evaluate the condition of COVID-19 patients, so we are interested in using the national early warning score-2 (NEWS 2) on COVID-19 patients [6]. The high mortality of COVID-19 patients in Indonesia made us interested in analyzing the association between NEWS-2 on mortality of COVID-19 patients in Indonesia.

* Corresponding author: Usman Hadi, Department of Internal Medicine, Faculty of Medicine, Universitas Airlangga – Dr. Soetomo General Academic Hospital, Jl. Mayjend Prof. Dr. Moestopo No. 6-8, Airlangga, Gubeng, Surabaya, East Java 60286, Indonesia.
E-mail address: usman.hadi2@fk.unair.ac.id (U. Hadi).

https://doi.org/10.1016/j.amsu.2022.103462
Received 29 January 2022; Received in revised form 25 February 2022; Accepted 28 February 2022
Available online 8 March 2022
2049-0801/© 2022 The Authors. Published by Elsevier Ltd on behalf of IJS Publishing Group Ltd. This is an open access article under the CC BY-NC-ND license. (http://creativecommons.org/licenses/by-nc-nd/4.0/)
2. Methods

2.1. Participants

Participants in this study were patients diagnosed with COVID-19. Participant criteria included >18 years old, confirmed COVID-19 based on real-time polymerase chain reaction (RT-PCR) [7,8] and X-ray/CT Scan of the thorax [9], did not receive oxygen therapy before, administration of antivirals, anti-inflammatory, anticoagulant, multivitamin, and previous symptomatic therapy, the patient received at least 1 × 24 h treatment and had the comorbid disease. Participant exclusion criteria included pregnant patients, patients who received positive pressure, went into shock, and had mental disorders. Participants and/or guardians had received explanations related to the research objectives, and participants were also required to fill out the consent form provided.

2.2. Methods of study

This study used a retrospective design by collecting data from June to July 2020. The number of participants in this study was 112 participants (case group = 56 participants and control group = 56 participants). The participants were collected using the quota sampling technique. The case group consisted of COVID-19 patients who had undergone treatment for >24 h and died, while the control group consisted of COVID-19 patients who had undergone treatment for >24 h and showed improvement. Our research report used strengthening the reporting of cohort studies in surgery (STROCSS) 2021 guideline [10]. The data in this study used participant characteristic data, NEWS-2 values, and the prognosis of COVID-19 treatment. The prognosis for COVID-19 treatment was dead and alive.

2.3. National early warning score examination

The NEWS-2 is a standard clinical scoring system developed to improve the detection of worsening in acutely ill patients. The tool consists of 6 assessment indicators that include respiratory rate, oxygen saturation, systolic blood pressure, pulse rate, level of consciousness or new confusion, and body temperature. In addition, two points are added for participants requiring supplementary oxygen treatment [6]. The NEWS-2 assessment is categorized into 3, namely low (0–4), middle (5–6), and severe (≥7) [11].

2.4. Statistical analysis

The measurement data were analyzed using IBM SPSS Statistics software version 25.0 (IBM Corp., Armonk, NY, USA) where the data were presented in the form of tables or figures. Statistical analysis used in this study included the Chi-squared test and regression logistic test with $p < 0.05$. The Chi-squared test was used to analyze the relationship between NEWS-2 on mortality of COVID-19 patients. Meanwhile, the regression logistic test was used to analyze the risk factors of comorbid disease on mortality of COVID-19 patients.

3. Results

3.1. Characteristic of participant

The mean age of participants was 51.92 ± 13.07 years, with a median of 53 (43–61) years. The youngest participant and oldest participants were 19 years old and 61 years old, respectively. Most participants were male (66; 58.93%) consisted of 32 in the case group (57.14%) and 34 in the control group (60.71%). Participants showed signs and symptoms of COVID-19 as follows: cough (82.14%), sniffles (47.32%), breathless (91.07%), fever (73.21%), anosmia (8.93%), diarrhea (33.04%), nausea/vomiting (37.5%), and abdominal pain (19.42%; Table 1). The difference in data between the case group and control group could be seen in Table 2.

3.2. Association of national early warning Score-2 on mortality of COVID-19

Most participants with a NEWS-2 score of >5 after undergoing treatment for >24 h died as many as 45 participants (40.18%). Meanwhile, the participants with NEWS-2 score of 5 after undergoing treatment for >24 h experienced improvements as many as 50 participants (44.64%; OR = 34.091; $p < 0.001$). The accuracy of NEWS-2’s assessment of mortality of COVID-19 patients had a sensitivity of 80.4%, specificity of 89.3%, a positive predictive value of 88.2%, and a negative predictive value of 82% (Fig. 1).

3.3. Association of comorbid disease on mortality of COVID-19 patient

Some participants had comorbid diseases as follows: cardiac disease (11.61%), type 2 diabetes mellitus/T2DM (42.86%), chronic kidney disease/CKD (22.32), obesity (4.46%), chronic lung disease (2.68%), and hypertension (38.39%). There were several comorbid diseases that had a significant relationship on mortality of COVID-19

| Variable   | COVID-19 Patients | $p$ |
|------------|-------------------|-----|
| Age        | 50.57 ± 11.29     | 0.002*|
| Treatment  | 17.73 ± 9.16      | 0.005*|
| GCS        | 13.96 ± 1.83      | 0.890 |
| Blood      |                   |     |
| pressure   |                   |     |
| Systolic   | 129.00 ± 17.29    | 0.436 |
| Diastolic  | 78.33 ± 10.53     | 0.574 |
| Pulse      | 88.93 ± 7.73      | <0.001**|
| Respiratory| 23.60 ± 2.25      | <0.001**|
| Temperature| 36.57 ± 0.63      | 0.736 |
| SO2        | 97.73 ± 0.78      | 0.251 |
| PaO2/FIO2  | 188.00 ± 134.89   | <0.001**|
| MAP        | 93.00 ± 143.83    | 0.455 |
| Hb         | 11.80 ± 2.69      | 0.142 |
| Leucocyte  | 9090.00 ± 5.84    | 0.083 |
| Platelet   | 2.25 ± 1.45       | 0.400 |
| NLR        | 6.88 ± 1.38       | 0.003*|
| ALC        | 940.00 ± 802.60   | 0.051 |
| CRP        | 12.70 ± 7.88      | 0.202 |
| D-dimer    | 2300.00 ± 6.17    | <0.001**|
| BUN        | 28.00 ± 44.69     | <0.001**|
| SK         | 1.40 ± 4.80       | <0.001**|
| SGOT       | 54.00 ± 165.47    | 0.415 |
| SPG       | 41.00 ± 41.43     | 0.600 |
| PCT        | 0.35 ± 2.54       | 0.079 |
| blood glucose level | 145.00 ± 73.60 | 0.005*|

Note: *significant <0.05; **significant <0.001.

Table 1

Frequency distribution of characteristic of participant.

| Characteristic | COVID-19 Patients |
|----------------|-------------------|
| Gender         |                   |
| Male           | 32 (57.14)        | 34 (60.71) |
| Female         | 24 (42.86)        | 22 (39.29) |
| Sign and Symptom|                 |
| Cough          | 43 (76.78)        | 49 (87.5) |
| Sniffles       | 13 (23.21)        | 40 (71.43) |
| Breathless     | 52 (92.86)        | 50 (89.28) |
| Fever          | 44 (78.57)        | 44 (76.86) |
| Anosmia        | 5 (8.93)          | 5 (8.93)  |
| Diarrhea       | 13 (23.21)        | 14 (25.0) |
| Nausea/vomiting| 21 (37.5)         | 21 (37.5) |
| Stomach pain   | 10 (17.86)        | 12 (21.42) |
patients, such as cardiac disease ($\beta = 5.907$; 1.107–31.527 95% CI; $p = 0.038$), T2DM ($\beta = 3.143$; 1.269–7.783 95% CI; $p = 0.013$), CKD ($\beta = 3.851$; 1.195–12.416 95% CI; $p = 0.024$), and hypertension ($\beta = 2.820$; 1.075–7.399 95% CI; $p = 0.035$; Table 3).

4. Discussion

In the current pandemic situation, early identification of patients at risk for severe disease and decision-making is very important in hospital care [6]. The NEWS-2 is recommended to evaluate COVID-19 patients after 24 h of treatment because COVID-19 patients are at risk of developing critical conditions during treatment [12]. Several previous studies also recommended that NEWS-2 could be used to evaluate the clinical condition of COVID-19 patients as NEWS-2 had a good performance of 0.842–0.894 [13]. The tool can help identify the risk of changing patient conditions requiring treatment in the intensive care unit (ICU) [5]. The NEWS-2 is the best assessment for assessing the prognostic of COVID-19 conditions requiring treatment in the intensive care unit (ICU) [5]. The NEWS-2 can also be used as a tool to identify the risk of death in COVID-19 patients, whereas many as 20% of COVID-19 patients treated in hospitals have died [6]. Another study also stated that NEWS-2 is a simple and fast tool in predicting patients over the age of >65 years [14]. The NEWS-2 can also predict patient deterioration quickly and simply in COVID-19 patients who need to get immediate treatment to minimize mortality in COVID-19 patients.

Hypertension increases the risk of mortality for COVID-19 patients, where COVID-19 patients with hypertension are at risk of developing critical conditions 2.6 times compared to patients without hypertension. Meanwhile, the mechanism of hypertension in COVID-19 is caused by SARS-CoV-2 attacking alveolar epithelial cells via angiotensin-converting enzyme 2 (ACE2) [15,16]. The cardiac disease has a similar mechanism as hypertension in terms of increasing the risk of mortality in COVID-19 patients [17,18]. Based on previous studies, CKD increases the risk of mortality for COVID-19 patients by 5.81 times as the level of pro-inflammatory cytokines increases in CKD patients, causing an increase in oxidative stress which ultimately results in an immune-inflammatory response. The resulting immune system damage may increase susceptibility to bacterial and viral infections, and this may be the main reason for the increased risk of pulmonary inflammation [19,20]. Based on previous research, it was stated that T2DM had a significant relationship with the mortality of COVID-19 patients, where T2DM patients infected with COVID-19 had a mortality risk of 1.75 [21].

Competing disease in COVID-19 needs to be considered in the use of NEWS-2 so that the monitoring and prognosis of patients in care are monitored and managed effectively and efficiently. There are some limitations in our study such as the study was conducted in a relatively small population, so a multicenter cohort study with a larger population is needed. The data collected were participant medical record data, which were incomplete.

5. Conclusion

The NEWS-2 can be used as a tool to identify the risk of death in COVID-19 patients. The correlation between NEWS-2 and the mortality of COVID-19 patients requires further research on a larger scale.

Sources of funding

Grant 2020 from Universitas Airlangga, Surabaya, Indonesia (664/UN3.14/PT/2020).

Ethical approval

We have conducted an ethical approval base on Declaration of Helsinki at Ethical Committee in Dr. Soetomo General Academic Hospital, Surabaya, Indonesia.

Consent

Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal on request.

Author contribution

All authors contributed toward data analysis, drafting and revising the paper, gave final approval of the version to be published and agree to be accountable for all aspects of the work.

Registration of research studies

1. Name of the registry: Health Research Ethics Comittee in the Dr. Soetomo General Academic Hospital, Surabaya, Indonesia
2. Unique Identifying number or registration ID: 1957/KEPK/IV/2020.
3. Hyperlink to your specific registration (must be publicly accessible and will be checked):

Guarantor

Usman Hadi.

Provenance and peer review

Not commissioned, externally peer-reviewed.

Declaration of competing interest

The authors have no conflict of interest.
Acknowledgment

Researchers greatly appreciate Joni Wahyuhadi as the director in Dr. Soetomo General Academic Hospital and Nasronudin as the director in Airlangga University Teaching Hospital who has facilitated us in conducting research and Soebagjio Adi Soelistijo for allowing us to get a research grant and facilitating us to collect data in internal medicine wards and intellectual discussion leading to research idea. We would like to thank “Fis Citra Ariyanto”.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.amsu.2022.103462.

References

[1] B. Nugraha, L.K. Wahyuni, H. Laswati, P. Kusumastuti, A.B. Tulaar, C. Gutenbrunner, COVID-19 pandemic in Indonesia: situation and challenges of rehabilitation medicine in Indonesia, Acta Medica Indonesia 52 (3) (2020) 299–305.

[2] Y. Mahendrahdita, N. Andayani, E.T. Hasti, M.D. Arifi, R.G.M. Siahaan, A. Solikha, et al., The capacity of the Indonesian Healthcare system to respond to COVID-19, Front. Public Health 9 (2021) 69819, https://doi.org/10.3389/fpubh.2021.69819.

[3] A. Rozaliyani, A.I. Savitri, F. Setianingrum, T.N. Shelly, V. Ratnasari, R. Kaswandiart, et al., Factors associated with death in COVID-19 patients in Jakarta, Indonesia: an epidemiological study, Acta Medica Indonesia 52 (3) (2020) 246–254.

[4] C. de Roquefaille, S. Bredin, J.B. Lascarrou, T. Soumagne, M. Cojocaru, B. G. Chousterman, et al., Timing and causes of death in severe COVID-19 patients, Crit. Care 25 (1) (2021) 228, https://doi.org/10.1186/s13054-021-03659-w.

[5] M. Covino, C. Sandroni, M. Santoro, L. Sabia, B. Simeoni, M.G. Bocci, et al., Predicting intensive care unit admission and death for COVID-19 patients in the emergency department using early warning scores, Resuscitation 156 (2020) 84–91, https://doi.org/10.1016/j.resuscitation.2020.08.124.

[6] M. Myrstad, H. Bøle-Hansen, A.A. Trøitza, E.L. Andersen, S. Nygård, A. Tveit, et al., National Early Warning Score 2 (NEWS2) on admission predicts severe disease and in-hospital mortality from Covid-19 - a prospective cohort study, Scand. J. Trauma Resuscitation Emerg. Med. 28 (1) (2020) 66, https://doi.org/10.1186/s13049-020-00764-3.

[7] T.D. Suryananda, R. Yudhawati, Association of serum KL-6 levels on COVID-19 severity: a cross-sectional study design with purposive sampling, Ann. Med. Surg. 2021 (69) (2012) 102673, https://doi.org/10.1016/j.amsu.2021.102673.

[8] G.N.R. Saputra, R. Yudhawati, M. Fizirah, Association of soluble receptor for advanced glycation end-products (sRAGE) serum on COVID-19 severity: a cross-sectional study, Ann. Med. Surg. 2022 (74) (2012) 103303, https://doi.org/10.1016/j.amsu.2022.103303.

[9] R. Setiawati, A. Widyaningroem, T. Handarini, F. Hayati, A.T. Bastja, A. Putri, et al., Modified chest X-ray scoring system in evaluating severity of COVID-19 patient in Dr. Soetomo general hospital Surabaya, Indonesia, Int. J. Gen. Med. 14 (2021) 2407–2412, https://doi.org/10.2147/ijgm.2021.310577.

[10] G. Mathew, R. Agha, STROCSS 2021: strengthening the reporting of cohort, cross-sectional and case-control studies in surgery, Int. J. Surg. 96 (2021) 106165, https://doi.org/10.1016/j.ijsu.2021.106165.

[11] G.B. Smith, O.C. Redfern, M.A. Pimentel, S. Gerry, G.S. Collins, J. Malycha, et al., The national early warning score 2 (NEWS2), Clin. Med. 19 (3) (2019) 260, https://doi.org/10.7861/cimemedicine.19.3-260.

[12] D. Richardson, M. Faisal, M. Fiori, K. Beaton, M. Mohammed, Use of the first National Early Warning Score recorded within 24 hours of admission to estimate the risk of in-hospital mortality in unplanned COVID-19 patients: a retrospective cohort study, BMJ Open 11 (2) (2021), e045721, https://doi.org/10.1136/bmjopen-2020-045721.

[13] I. Kostakis, G.B. Smith, D. Prytherch, P. Meredith, C. Price, A. Chauhan, The performance of the National Early Warning Score and National Early Warning Score 2 in hospitalised patients infected by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Resuscitation 159 (2021) 150–157, https://doi.org/10.1016/j.resuscitation.2020.10.039.

[14] I. Kim, H. Song, H.J. Kim, K.N. Park, S.H. Kim, S.H. Oh, et al., Use of the National Early Warning Score for predicting in-hospital mortality in older adults admitted to the emergency department, Clin. Exp. Emerg. Med. 7 (1) (2020) 61–66, https://doi.org/10.15441/ceem.19.0036.

[15] R. Pranata, M.A. Lim, I. Huang, S.B. Raharjo, A.A. Lukito, Hypertension is associated with increased mortality and severity of disease in COVID-19 pneumonia: a systematic review, meta-analysis and meta-regression, J. Renin-Angiotensin-Aldosterone Syst. JRAAS : J. Renin-Angiotensin-Aldosterone Syst. JRAAS 21 (2) (2020), https://doi.org/10.1177/147032020926899.

[16] Y. Du, N. Zhou, W. Zha, Y. Lv, Hypertension is a clinically important risk factor for critical illness and mortality in COVID-19: a meta-analysis, Nutri. Metabol. Cardiovasc. Dis. : Nutri. Metabol. Cardiovasc. Dis. 31 (3) (2021) 745–755, https://doi.org/10.1016/j.jnme.2020.12.009.

[17] M. Zuin, G. Rigatelli, G. Zuliani, C. Bilato, P. Zonzin, L. Roncon, Incidence and mortality risk in coronavirus disease 2019 patients complicated by acute cardiac injury: systematic review and meta-analysis, J. Cardiovasc. Med. 21 (10) (2020) 759–764, https://doi.org/10.12968/jcm.2020.21.10.1747.

[18] B.E. Park, J.H. Lee, H.K. Park, H.N. Kim, S.Y. Jang, M.H. Bae, et al., Impact of cardiovascular risk factors and cardiovascular diseases on outcomes in patients hospitalized with COVID-19 in Daegu Metropolitan City, J. Kor. Med. Sci. 36 (2) (2021) e15, https://doi.org/10.3346/jkms.2021.36.e15.

[19] R. Cai, J. Zhang, Y. Zhu, L. Liu, Y. Liu, Q. He, Mortality in chronic kidney disease patients with COVID-19: a systematic review and meta-analysis, Int. Urol. Nephrol. 53 (8) (2021) 1623–1629, https://doi.org/10.1007/s11255-020-02740-3.

[20] S.S. Jdiaa, R. Mansour, A. El Alayli, A. Gautam, P. Thomas, R.A. Mustafa, COVID-19 and chronic kidney disease: an updated overview of reviews, J. Renal. Sci. 147032032092689.

[21] Z.H. Wu, Y. Tang, Q. Cheng, Diabetes increases the mortality of patients with COVID-19, Front. Public Health 9 (2021) 649819, https://doi.org/10.3389/fpubh.2021.649819.